Metropolitan Life Insurance Company (MetLife)’s Vir Biotechnology VIR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,869	Closed	-$49.3K	–	2041
2024 Q1	$49.3K	Hold	4,869	–	–	﹤0.01%	1410
2023 Q4	$49K	Hold	4,869	–	–	﹤0.01%	1460
2023 Q3	$45.6K	Buy	4,869 +293	+6%	+$4.18K	﹤0.01%	1454
2023 Q2	$112K	Buy	+4,576	New	+$115K	0.01%	966
2023 Q1	–	Sell	-4,382	Closed	-$111K	–	2470
2022 Q4	$111K	Hold	4,382	–	–	0.01%	994
2022 Q3	$84.5K	Hold	4,382	–	–	﹤0.01%	1115
2022 Q2	$112K	Buy	4,382 +472	+12%	+$11K	﹤0.01%	996
2022 Q1	$101K	Sell	3,910 -11,534	-75%	-$342K	﹤0.01%	1188
2021 Q4	$647K	Sell	15,444 -827	-5%	-$32.4K	0.01%	1253
2021 Q3	$708K	Buy	+16,271	New	+$704K	0.01%	1203
2021 Q2	–	Sell	-15,024	Closed	-$770K	–	2889
2021 Q1	$770K	Sell	15,024 -667	-4%	-$35.9K	0.01%	1133
2020 Q4	$420K	Hold	15,691	–	–	0.01%	1470
2020 Q3	$539K	Buy	15,691 +1,477	+10%	+$63.6K	0.01%	1164
2020 Q2	$582K	Buy	14,214 +11,715	+469%	+$393K	0.01%	1088
2020 Q1	$85.6K	Buy	+2,499	New	+$67.2K	﹤0.01%	2124

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s VIR Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Vir Biotechnology (VIR) in Q2 2024, closing a stake of 4,869 shares — an estimated $49.3K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in VIR in Q1 2020 and held it in 15 quarters. The position peaked at $770K in Q1 2021. 215 funds tracked by Wall St. Rank hold VIR as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Vir Biotechnology position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 4,869 Vir Biotechnology shares in Q2 2024, an estimated $49.3K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Vir Biotechnology in Q1 2020 and held it in 15 quarters.
Metropolitan Life Insurance Company (MetLife)'s Vir Biotechnology position peaked at $770K in Q1 2021.
215 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.